Scholarlink

The introduction of immunotherapies in the treatment of metastatic lung cancer has brought a major change to oncology practices with a high impact on patient prognosis. As a next step, these substances are currently being tested for the use in the neoadjuvant setting, showing promise in early phase trials, such as pathological response and R0 rates. Many questions remain to be answered before this is implemented in daily practice; the according phase III trials are impatiently awaited.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunotherapy for Non-small Cell Lung Cancer

  • 工具书词条

  • 发表日期：

    2025年

查看全文
  • Fabrizio Minervini,
  • Laura Boschetti,
  • Esther Pardo

摘要

The introduction of immunotherapies in the treatment of metastatic lung cancer has brought a major change to oncology practices with a high impact on patient prognosis. As a next step, these substances are currently being tested for the use in the neoadjuvant setting, showing promise in early phase trials, such as pathological response and R0 rates. Many questions remain to be answered before this is implemented in daily practice; the according phase III trials are impatiently awaited.